{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T01:17:22Z","timestamp":1775956642587,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,19]],"date-time":"2021-09-19T00:00:00Z","timestamp":1632009600000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.canrad.2020.05.005","type":"journal-article","created":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T13:04:50Z","timestamp":1596287090000},"page":"699-705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Radioresistant tumours: From identification to targeting"],"prefix":"10.1016","volume":"24","author":[{"given":"\u00c9.","family":"Cohen-Jonathan-Moyal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Vendrely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Motte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Balosso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Thariat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2020.05.005_bib0210","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1038\/sj.onc.1205838","article-title":"The radioprotective effect of the 24kDa FGF-2 isoform in HeLa cells is related to an increased expression and activity of the DNA dependent protein kinase (DNA-PK) catalytic subunit","volume":"21","author":"Ader","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.canrad.2020.05.005_bib0215","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.ejca.2013.02.033","article-title":"alphavbeta3 integrin and fibroblast growth factor receptor 1 (FGFR1): prognostic factors in a phase I-II clinical trial associating continuous administration of tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma","volume":"49","author":"Ducassou","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2020.05.005_bib0220","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1158\/0008-5472.CAN-15-2058","article-title":"FGFR1 Induces glioblastoma radioresistance through the PLCgamma\/Hif1alpha pathway","volume":"76","author":"Gouaze-Andersson","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.canrad.2020.05.005_bib0225","doi-asserted-by":"crossref","first-page":"31637","DOI":"10.18632\/oncotarget.25827","article-title":"FGFR1\/FOXM1 pathway: a key regulator of glioblastoma stem cells radioresistance and a prognosis biomarker","volume":"9","author":"Gouaze-Andersson","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.canrad.2020.05.005_bib0230","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1158\/0008-5472.CAN-08-2158","article-title":"Alphavbeta3\/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma","volume":"69","author":"Skuli","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.canrad.2020.05.005_bib0235","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1091\/mbc.e04-12-1082","article-title":"Hypoxia-inducible factor regulates alphavbeta3 integrin cell surface expression","volume":"16","author":"Cowden Dahl","year":"2005","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.canrad.2020.05.005_bib0240","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1016\/j.ejca.2013.05.003","article-title":"Radiation-induced mitotic cell death and glioblastoma radioresistance: a new regulating pathway controlled by integrin-linked kinase, hypoxia-inducible factor 1 alpha and survivin in U87 cells","volume":"49","author":"Lanvin","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2020.05.005_bib0245","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3109\/0284186X.2015.1071496","article-title":"Robustness of quantitative hypoxia PET image analysis for predicting local tumor control","volume":"54","author":"Monnich","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2020.05.005_bib0250","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ijrobp.2019.01.077","article-title":"Tumor voxel dose\u2013response matrix and dose prescription function derived using (18F)-FDG PET\/CT images for adaptive dose-painting by number","volume":"104","author":"Yan","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2020.05.005_bib0255","doi-asserted-by":"crossref","first-page":"69518","DOI":"10.18632\/oncotarget.11680","article-title":"Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma","volume":"7","author":"Vartanian","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canrad.2020.05.005_bib0260","doi-asserted-by":"crossref","first-page":"51530","DOI":"10.18632\/oncotarget.17887","article-title":"HPV-associated differential regulation of tumor metabolism in oropharyngeal head and neck cancer","volume":"8","author":"Jung","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canrad.2020.05.005_bib0265","doi-asserted-by":"crossref","first-page":"e1056442","DOI":"10.1080\/2162402X.2015.1056442","article-title":"Hypoxia induces macrophage polarization and re-education toward an M2 phenotype in U87 and U251 glioblastoma models","volume":"5","author":"Leblond","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canrad.2020.05.005_bib0270","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1038\/s41467-018-07470-w","article-title":"Tumour-vasculature development via endothelial-to-mesenchymal transition after radiotherapy controls CD44v6(+) cancer cell and macrophage polarization","volume":"9","author":"Choi","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.canrad.2020.05.005_bib0275","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13550-019-0556-z","article-title":"Voxel-based identification of local recurrence subregions from pretreatment PET\/CT for locally advanced head and neck cancers","volume":"9","author":"Beaumont","year":"2019","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.canrad.2020.05.005_bib0280","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ijrobp.2007.10.039","article-title":"Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study","volume":"70","author":"Laprie","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2020.05.005_bib0285","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12885-019-5317-x","article-title":"Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging","volume":"19","author":"Laprie","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canrad.2020.05.005_bib0290","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1080\/0284186X.2018.1512753","article-title":"Dose painting for re-irradiation of head and neck cancer","volume":"57","author":"Skjotskift","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2020.05.005_bib0295","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijrobp.2019.09.003","article-title":"Complexity in radiation therapy: it's complicated","volume":"106","author":"Kamperis","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2020.05.005_bib0300","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2967\/jnumed.116.188367","article-title":"Phase II study of a radiotherapy total dose increase in hypoxic lesions identified by (18F)-misonidazole PET\/CT in patients with non-small cell lung carcinoma (RTEP5 Study)","volume":"58","author":"Vera","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.canrad.2020.05.005_bib0305","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/hed.24892","article-title":"Long-term outcome of (18F)-fluorodeoxyglucose-positron emission tomography-guided dose-painting for head and neck cancer: matched case-control study","volume":"39","author":"Berwouts","year":"2017","journal-title":"Head Neck"},{"key":"10.1016\/j.canrad.2020.05.005_bib0310","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13014-017-0776-1","article-title":"Do selective radiation dose escalation and tumour hypoxia status impact the locoregional tumour control after radiochemotherapy of head and neck tumours? The ESCALOX protocol","volume":"12","author":"Porsche","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2020.05.005_bib0315","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13014-018-1147-2","article-title":"FDG and FMiso PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer","volume":"13","author":"Thureau","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2020.05.005_bib0320","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/0284186X.2020.1714720","article-title":"Radiation dose-painting with protons vs. photons for head-and-neck cancer","volume":"59","author":"Hakansson","year":"2020","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2020.05.005_bib0325","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3109\/0284186X.2010.498440","article-title":"Feasibility of dose painting using volumetric modulated arc optimization and delivery","volume":"49","author":"Korreman","year":"2010","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2020.05.005_bib0330","doi-asserted-by":"crossref","first-page":"i90","DOI":"10.1093\/jrr\/rrw007","article-title":"The impact of hypoxia and its modification of the outcome of radiotherapy","volume":"57","author":"Horsman","year":"2016","journal-title":"J Radiat Res"},{"key":"10.1016\/j.canrad.2020.05.005_bib0335","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/mp.12874","article-title":"The relative biological effectiveness for carbon, nitrogen, and oxygen ion beams using passive and scanning techniques evaluated with fully 3D silicon microdosimeters","volume":"45","author":"Tran","year":"2018","journal-title":"Med Phys"},{"key":"10.1016\/j.canrad.2020.05.005_bib0340","doi-asserted-by":"crossref","first-page":"17016","DOI":"10.1038\/srep17016","article-title":"Kill-painting of hypoxic tumours in charged particle therapy","volume":"5","author":"Tinganelli","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.canrad.2020.05.005_bib0345","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.canrad.2009.08.141","article-title":"Rationale for carbon ion therapy in high-grade glioma based on a review and a meta-analysis of neutron beam trials","volume":"14","author":"Maucort-Boulch","year":"2010","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2020.05.005_bib0350","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00259-017-3677-5","article-title":"(18F)-FMiso PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis","volume":"44","author":"Bekaert","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.canrad.2020.05.005_bib0355","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.canrad.2020.01.010","article-title":"Imaging issues specific to hadrontherapy (proton, carbon, helium therapy and other charged particles) for radiotherapy planning, setup, dose monitoring and tissue response assessment","volume":"24","author":"Thariat","year":"2020","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2020.05.005_bib0360","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/jrr\/rrt033","article-title":"A prospective clinical trial of tumor hypoxia imaging with (18F)-fluoromisonidazole positron emission tomography and computed tomography (F-Miso PET\/CT) before and during radiation therapy","volume":"54","author":"Tachibana","year":"2013","journal-title":"J Radiat Res"},{"key":"10.1016\/j.canrad.2020.05.005_bib0365","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijrobp.2016.04.027","article-title":"Strategy of using intratreatment hypoxia imaging to selectively and safely guide radiation dose de-escalation concurrent with chemotherapy for locoregionally advanced human papillomavirus-related oropharyngeal carcinoma","volume":"96","author":"Lee","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2020.05.005_bib0370","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijrobp.2007.08.036","article-title":"Reproducibility of intratumor distribution of (18F)-fluoromisonidazole in head and neck cancer","volume":"70","author":"Nehmeh","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2020.05.005_bib0375","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.ijrobp.2014.08.016","article-title":"[18F]-Fluoromisonidazole positron emission tomography\/computed tomography visualization of tumor hypoxia in patients with chordoma of the mobile and sacrococcygeal spine","volume":"90","author":"Cheney","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2020.05.005_bib0380","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3389\/fmed.2019.00117","article-title":"Hypoxia imaging and adaptive radiotherapy: a state-of-the-art approach in the management of glioma","volume":"6","author":"G\u00e9rard","year":"2019","journal-title":"Front Med"},{"key":"10.1016\/j.canrad.2020.05.005_bib0385","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3390\/ijms21010133","article-title":"Hadrontherapy interactions in molecular and cellular biology","volume":"21","author":"Thariat","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.canrad.2020.05.005_bib0390","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3390\/cancers11040468","article-title":"ROS Production and distribution: a new paradigm to explain the differential effects of X-ray and carbon ion irradiation on cancer stem cell migration and invasion","volume":"11","author":"Wozny","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canrad.2020.05.005_bib0395","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bulcan.2014.10.002","article-title":"Nanoparticles and radiation therapy","volume":"102","author":"Calugaru","year":"2015","journal-title":"Bull Cancer"},{"key":"10.1016\/j.canrad.2020.05.005_bib0400","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S1470-2045(19)30326-2","article-title":"NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial","volume":"20","author":"Bonvalot","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2020.05.005_bib0405","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.canrad.2019.07.134","article-title":"Use of nanoparticles as radiosensitizing agents in radiotherapy: state of play","volume":"23","author":"Verry","year":"2019","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2020.05.005_bib0410","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1158\/1055-9965.EPI-18-0881","article-title":"The clinicopathologic and prognostic value of hypoxia-inducible factor-2alpha in cancer patients: a systematic review and meta-analysis","volume":"28","author":"Luo","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321820301669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321820301669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:35:58Z","timestamp":1761136558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321820301669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":41,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1278321820301669"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2020.05.005","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radioresistant tumours: From identification to targeting","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2020.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}